Abiraterone acetate plus prednisone aids survival in castration-resistant prostate cancer
The second interim analysis of the COU-AA-302 trial revealed a strong overall survival trend favoring abiraterone and prednisone over placebo and prednisone in men with asymptomatic or mildly symptomatic, chemotherapy-naive, metastatic, castration-resistant prostate cancer. The results led to the unblinding of the phase III trial and crossover treatment for the control arm. Dr. Charles J. Ryan, who presented the study results at the 2012 annual meeting of the American Society of Clinical Oncology in Chicago, discusses the implications and other notable prostate cancer research at the meeting in an interview with Dr. Walter Stadler of the University of Chicago.
The content of the videos, articles and all statements expressed therein do not necessarily reflect the opinions or views of the Editors, Authors or Reviewers of European Urology.